Subject(s)
Anemia, Sideroblastic , HIV Infections , Heterocyclic Compounds, 3-Ring , Oxazines , Piperazines , Pyridones , Humans , Pyridones/adverse effects , Heterocyclic Compounds, 3-Ring/adverse effects , Piperazines/adverse effects , Anemia, Sideroblastic/chemically induced , Anemia, Sideroblastic/drug therapy , HIV Infections/drug therapy , HIV Infections/complications , Male , HIV Integrase Inhibitors/adverse effects , HIV Integrase Inhibitors/therapeutic use , Middle AgedSubject(s)
Anemia, Sideroblastic , Erythroblasts , Linezolid/adverse effects , Aged , Anemia, Sideroblastic/chemically induced , Anemia, Sideroblastic/metabolism , Anemia, Sideroblastic/pathology , Erythroblasts/metabolism , Erythroblasts/pathology , Female , Humans , Linezolid/administration & dosage , Orbital Cellulitis/drug therapy , Orbital Cellulitis/metabolism , Orbital Cellulitis/pathology , Renal Insufficiency/drug therapy , Renal Insufficiency/metabolism , Renal Insufficiency/pathology , Sepsis/drug therapy , Sepsis/metabolism , Sepsis/pathology , Staphylococcal Infections/drug therapy , Staphylococcal Infections/metabolism , Staphylococcus aureusSubject(s)
Anemia, Sideroblastic/diagnosis , Copper/deficiency , Myelodysplastic Syndromes/diagnosis , Neutropenia/diagnosis , Zinc/pharmacology , Anemia, Sideroblastic/chemically induced , Anemia, Sideroblastic/drug therapy , Biopsy , Bone Marrow/pathology , Bone Marrow Examination , Copper/blood , Diagnosis, Differential , Humans , Hyperplasia , Male , Middle Aged , Neutropenia/chemically induced , Neutropenia/drug therapy , Zinc/bloodSubject(s)
Acetamides/adverse effects , Anemia, Sideroblastic/blood , Anemia, Sideroblastic/chemically induced , Anti-Infective Agents/adverse effects , Oxazolidinones/adverse effects , Adult , Aged , Anemia, Sideroblastic/diagnosis , Bone Marrow Cells/drug effects , Bone Marrow Cells/pathology , Cohort Studies , Female , Humans , Linezolid , Male , Middle Aged , Retrospective StudiesSubject(s)
Anemia, Sideroblastic/chemically induced , Antitubercular Agents/adverse effects , Pyrazinamide/adverse effects , Tuberculosis, Pulmonary/drug therapy , Adult , Anemia, Sideroblastic/diagnosis , Anemia, Sideroblastic/therapy , Humans , Male , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/microbiologySubject(s)
Acetamides/adverse effects , Acidosis/chemically induced , Acute Coronary Syndrome/chemically induced , Anti-Bacterial Agents/adverse effects , Oxazolidinones/adverse effects , Pulmonary Edema/chemically induced , Rhabdomyolysis/chemically induced , Acetamides/therapeutic use , Acute Coronary Syndrome/drug therapy , Anemia, Sideroblastic/chemically induced , Anemia, Sideroblastic/therapy , Anti-Bacterial Agents/therapeutic use , Bicarbonates/therapeutic use , Combined Modality Therapy , Diuretics/therapeutic use , Erythrocyte Transfusion , Fracture Fixation, Internal , Humans , Linezolid , Male , Middle Aged , Nitroglycerin/therapeutic use , Oxazolidinones/therapeutic use , Pulmonary Edema/drug therapy , Staphylococcal Infections/drug therapy , Staphylococcal Infections/surgery , Staphylococcus haemolyticus , Surgical Wound Infection/drug therapy , Surgical Wound Infection/surgery , Tibial Fractures/surgerySubject(s)
Anemia, Sideroblastic/chemically induced , Antitubercular Agents/adverse effects , Bone Marrow/pathology , Peritonitis, Tuberculous/drug therapy , Pyrazinamide/adverse effects , 5-Aminolevulinate Synthetase/antagonists & inhibitors , Anemia, Sideroblastic/blood , Anemia, Sideroblastic/drug therapy , Antitubercular Agents/administration & dosage , Antitubercular Agents/therapeutic use , Aza Compounds/administration & dosage , Aza Compounds/therapeutic use , Chemical and Drug Induced Liver Injury/etiology , Drug Therapy, Combination , Ethambutol/administration & dosage , Ethambutol/therapeutic use , Female , Fluoroquinolones , Hemolysis/drug effects , Humans , Isoniazid/administration & dosage , Isoniazid/adverse effects , Isoniazid/therapeutic use , Middle Aged , Moxifloxacin , Peritonitis, Tuberculous/complications , Pyrazinamide/administration & dosage , Pyrazinamide/therapeutic use , Pyridoxine/therapeutic use , Quinolines/administration & dosage , Quinolines/therapeutic use , Rifampin/administration & dosage , Rifampin/therapeutic use , alpha-Thalassemia/complicationsSubject(s)
Acetamides/adverse effects , Anemia, Refractory/chemically induced , Anemia, Sideroblastic/chemically induced , Anti-Bacterial Agents/adverse effects , Oxazolidinones/adverse effects , Postoperative Complications/chemically induced , Prosthesis-Related Infections/drug therapy , Acetamides/therapeutic use , Aged , Anemia, Refractory/blood , Anemia, Refractory/diagnosis , Anemia, Refractory/drug therapy , Anemia, Refractory/therapy , Anemia, Sideroblastic/blood , Anemia, Sideroblastic/diagnosis , Anemia, Sideroblastic/drug therapy , Anemia, Sideroblastic/therapy , Anti-Bacterial Agents/therapeutic use , Arthroplasty , Arthroplasty, Replacement, Hip , Arthroplasty, Replacement, Knee , Combined Modality Therapy , Comorbidity , Diabetes Mellitus, Type 2/complications , Diagnosis, Differential , Erythrocyte Transfusion , Erythropoietin/therapeutic use , Female , Humans , Linezolid , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Obesity, Morbid/complications , Oxazolidinones/therapeutic use , Polypharmacy , Postoperative Complications/blood , Postoperative Complications/diagnosis , Postoperative Complications/drug therapy , Postoperative Complications/therapy , Prosthesis-Related Infections/microbiology , Prosthesis-Related Infections/surgery , ReoperationABSTRACT
Linezolid is an effective and well-tolerated antibiotic for the treatment of infections caused by Gram-positive pathogens. Some reports have shown that linezolid treatment for more than 2 weeks has been associated with reversible bone marrow suppression, especially thrombocytopenia and anemia. We encountered a case of sideroblastic anemia following prolonged linezolid therapy in a laryngeal cancer patient. He received linezolid therapy for multiple abscesses due to MRSA. Before treatment, the Hb level was 12.5 g/dl and then slowly decreased to 5.9 g/dl for 2 months during treatment. Ringed sideroblasts were detected in the bone marrow. Linezolid was discontinued and the Hb level was slowly increased. This case was considered to reflect a rare complication of linezolid therapy.
Subject(s)
Acetamides/adverse effects , Anemia, Sideroblastic/chemically induced , Anti-Infective Agents/adverse effects , Oxazolidinones/adverse effects , Abscess/drug therapy , Acetamides/administration & dosage , Aged , Humans , Laryngeal Neoplasms , Linezolid , Male , Methicillin-Resistant Staphylococcus aureus , Oxazolidinones/administration & dosage , Staphylococcal Infections/drug therapyABSTRACT
The myelodysplastic syndromes (MDS) consist of a group of diverse hematological disorders that carry an increased risk of transforming into acute myeloid leukemia. They may appear de novo and without obvious cause (primary or de novo MDS) or be induced by certain mutagenic environmental or therapeutic toxins (secondary MDS). Excessive exposures to benzene are generally considered to be a potential environmental risk factor for both MDS and acute myeloid leukemia. However, such risk is unproven for each disease component within the MDS classification. A critical review of the refractory sideroblastic disorders strongly suggests that benzene exposure is not a potential cause of this distinct and still-evolving subset of MDS. The widely disparate nature of MDS suggests that epidemiologic studies can only provide meaningful data on associations and potential causation of its component syndromes by a disease-specific analysis, as is currently advocated for other hematological malignancies.
Subject(s)
Anemia, Sideroblastic/chemically induced , Benzene/toxicity , Environmental Pollutants/toxicity , Myelodysplastic Syndromes/chemically induced , Anemia, Sideroblastic/physiopathology , Erythropoiesis/physiology , Humans , Leukemia, Myeloid, Acute/chemically induced , Leukemia, Myeloid, Acute/physiopathology , Myelodysplastic Syndromes/physiopathology , Risk FactorsABSTRACT
An acquired form of sideroblastic anemia has been described in association with several drugs, especially anti-microbial agents. A case of sideroblastic anemia is presented in a patient with a left ventricular assist device drive-line infection who was receiving linezolid, an antibiotic used for serious infections with gram-positive organisms. This patient's anemia resolved after discontinuation of the drug; he subsequently underwent an uncomplicated orthotopic heart transplant with no recurrence of anemia. As linezolid has been shown to have hematologic side effects, blood count monitoring is recommended in patients receiving this drug for long-term therapy.
Subject(s)
Acetamides/adverse effects , Anemia, Sideroblastic/chemically induced , Anti-Infective Agents/adverse effects , Heart-Assist Devices , Oxazolidinones/adverse effects , Staphylococcal Infections/drug therapy , Acetamides/therapeutic use , Anti-Infective Agents/therapeutic use , Heart Transplantation , Humans , Linezolid , Male , Middle Aged , Oxazolidinones/therapeutic use , Prosthesis-Related Infections/drug therapy , Staphylococcus epidermidis , Waiting ListsABSTRACT
OBJECTIVES AND METHODS: To describe cases of fusidic acid-associated sideroblastic anaemia from the French Pharmacovigilance database. RESULTS: Six cases of sideroblastic anaemia associated with oral fusidic acid treatment were retrieved. Four females and two males (mean age 65.3 yr) developed severe anaemia (mean haemoglobin level: 6.9 g/dL) within 32-190 d (mean: 81 d) of treatment. Bone marrow aspirates showed dyserythropoiesis and ringed sideroblasts in all patients. Four patients required repeated blood transfusions. After fusidic acid discontinuation in five patients, complete recovery was obtained. In one patient, rechallenge with fusidic acid resulted in recurrence of anaemia that resolved after definitive discontinuation of the drug. CONCLUSION: Our data indicate that fusidic acid should be added to the list of drugs that can cause sideroblastic anaemia.
Subject(s)
Anemia, Sideroblastic/chemically induced , Fusidic Acid/adverse effects , Aged , Anemia, Sideroblastic/therapy , Bacterial Infections/drug therapy , Blood Transfusion , Drug Therapy, Combination/therapeutic use , Female , Humans , Hyperbilirubinemia/chemically induced , Male , Middle Aged , Neutropenia/chemically induced , Peripheral Nervous System Diseases/chemically induced , Pristinamycin/administration & dosage , Pristinamycin/adverse effects , Recurrence , Thrombocytopenia/chemically inducedABSTRACT
Zinc is a common supplement and is widely available as a standard component of many over-the-counter products. A number of reports have identified an association between excessive zinc intake and severe cytopenia. We report a case of zinc-induced copper deficiency in a young adult to illustrate this under-recognized cause of anemia and neutropenia.
Subject(s)
Anemia, Sideroblastic/chemically induced , Dietary Supplements/adverse effects , Neutropenia/chemically induced , Zinc/adverse effects , Adult , Female , Humans , Nonprescription Drugs , Pantothenate Kinase-Associated Neurodegeneration/drug therapySubject(s)
Acetamides/adverse effects , Anemia, Sideroblastic/chemically induced , Anti-Bacterial Agents/adverse effects , Oxazolidinones/adverse effects , Acetamides/therapeutic use , Aged , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Drug Therapy, Combination/therapeutic use , Female , Humans , Linezolid , Oxazolidinones/therapeutic use , Surgical Wound Infection/drug therapyABSTRACT
Eight of 35 patients with cancer receiving COL-3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases. Am. J. Hematol. 67:51-53, 2001. Published 2001 Wiley-Liss, Inc.